Global Antisense and RNAi Therapeutics Market: Overview
The rising incidence of coronary artery diseases, cardiac ailments, and neurodegenerative and infectious diseases has led to the demand for antisense and RNai therapeutics. The market exhibits a strong pipeline of product and is looking forward to introduce several advancements in the RNAi drug delivery technology. These factors will act as high growth rendering drivers in the coming years.
The global antisense and RNAi therapeutics market is still at a nascent stage, however, will product approvals on cards, the market is forecast to report strong growth between 2015 and 2023. Market players are expecting lucrative prospects as collaborations between RNA licensing therapeutic developers and pharmaceutical giants gain pace.
The report provides a comprehensive analysis of the global antisense and RNAi therapeutics market covering present product portfolio and those in pipeline. Factors influencing the market’s trajectory over the forecast period are studied in detail. Information included in the report is obtained via trusted industrial sources and substantiated using decisive data. Information comprised in the report is thus intended to help stakeholders gain a better perspective of the global antisense and RNAi therapeutics market.
Global Antisense and RNAi Therapeutics Market: Trends and Opportunities
Besides collaborations between therapeutic developments and pharmaceutical companies, alliances are taking place between operating entities and outsourcing partners. These alliances have allowed operating entities outsource research and licensing activities to third-party partners while focusing on their core competencies. These recent trends, as per industry veterans, hold strong growth potential for the overall market.
Moreover, the discovery of ribonucleic acid silencing has paved avenues for treatments, which are developed using interference mechanism of RNA. However, the market is yet to pick desired pace, as complexities with regards to delivering target molecules to target organs continue to haunt scientists and drug developers. Nevertheless, with the advent of novel nano-technology oriented techniques, which exhibited higher efficacy in target delivery, has enabled the industry exhibit positive trajectory. Also with the implementation of favorable government initiatives and as a result of external funding, the global antisense and RNAi therapeutics market will exhibit strong growth in the coming years.
Global Antisense and RNAi Therapeutics Market: Regional Outlook
The global antisense and RNAi therapeutics market can be broadly classified under North America, Latin America, Europe, the Middle East & Africa, and Asia Pacific based on region. Of these, North America has showcased the most lucrative opportunities in the past and has thus contributed a considerable share to the overall industry. The region boasts a rising number clinical trials and government policies therein support the process of initiation for developing antisense therapeutics. Besides this, a large number of clinical laboratories are engaged in research and development activities in the field, which has warranted significant growth to the North America market in the coming years. It is important to note here, that clinical laboratories in North America also contribute to revenue generation via product and platform licensing. The potential commercialization of a few candidates under research and development will help the antisense and RNAi therapeutics market to pick up pace in North America in the near future.
However, in the period post commercialization of these therapies, opportunities in Asia Pacific are expected to get more lucrative, exhibiting a higher growth rate. The rising government spending toward research and development in topical, besides other forms of siRNA delivery techniques is a strong factor aiding the market’s trajectory in Asia Pacific.
Global Antisense and RNAi Therapeutics Market: Vendor Landscape
Isis Pharmaceuticals, Alnylam Pharmaceuticals, Silence Therapeutics, Antisense Therapeutics, Santaris, and miRagen Therapeutics are some of the leading players in the global antisense and RNAi therapeutics market. To gain a stronger foothold, these companies are majorly focusing on strategic collaborations and licensing deals.
Geographies analyzed under this research report include
- North America
- Asia Pacific
- Middle East and Africa
- Latin America
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.